Literature DB >> 21270755

DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.

A I Svirnovski1, T F Serhiyenka, A M Kustanovich, P V Khlebko, V V Fedosenko, I B Taras, A V Bakun.   

Abstract

AIM: To perform the comparative study of the effects of DNA-dependent protein kinase (DNA-PK) inhibitors vanillin and NU7026, ataxia telangiectasia mutated kinase (ATM)/ ATM and Rad3 related (ATR) kinase inhibitor caffeine and multidrug resistance (MDR) protein modulator cyclosporine A (CsA) on fludarabine resistant and sensitive lymphocytes from chronic lymphocytic leukemia (CLL) patients.
METHODS: Cells sensitivity in vitro was determined with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). DNA-PKs and ATM expression in CLL cells was evaluated using Western blotting. Multidrug tansporter protein expression and function was assessed by flow cytometry. Pro- or anti-apoptotic genes (BAX, LICE BCL-2, BCL-XS FLICE, FAS, TRAIL) expression on mRNA level was evaluated.
RESULTS: Caffeine, vanillin, NU7026 and CsA increased fludarabine cytotoxicity against fludarabine-resistant CLL cells samples in comparison with sensitive cell samples. However, fludarabine-sensitive CLL samples were sensitized with inhibitors to a greater extent compared with resistant CLL samples. ATM expression increased in fludarabine-resistant CLL samples, but no apparent correlation between DNA-PKs level and fludarabine sensitivity in vitro or sensitization effect of DNA-PK inhibitors were observed. Fludarabine-resistant CLL lymphocytes showed tendency for depressed MDR efflux and decreased level of mRNA of pro-apoptotic gene BCL-XS.
CONCLUSION: Absence of any definite conformity between fludarabine-resistant cell susceptibility to combined action of fludarabine and inhibitors, and molecular pathways that might be involved in this process does not exclude drugs synergy in fludarabine-resistant cells that could be used for overcoming resistance to nucleoside analogs in CLL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21270755

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  8 in total

1.  Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA.

Authors:  Takashi Kon; Xiuwu Zhang; Qian Huang; Zhonghui Yang; Shanling Liu; Bin Yan; Fang Li; He Wang; Chuan-Yuan Li
Journal:  Transl Cancer Res       Date:  2012-06       Impact factor: 1.241

2.  Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.

Authors:  Ya Zhang; Xiangxiang Zhou; Ying Li; Yangyang Xu; Kang Lu; Peipei Li; Xin Wang
Journal:  Oncogene       Date:  2018-06-12       Impact factor: 9.867

3.  Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation.

Authors:  Hong Qiong Yan; Xiao Bo Huang; Shi Zhong Ke; Yi Na Jiang; Yue Hua Zhang; Yi Nan Wang; Juan Li; Feng Guang Gao
Journal:  Cancer Sci       Date:  2014-09-08       Impact factor: 6.716

4.  Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Authors:  Annalisa Lonetti; Alessandra Cappellini; Alice Bertaina; Franco Locatelli; Andrea Pession; Francesca Buontempo; Camilla Evangelisti; Cecilia Evangelisti; Ester Orsini; Laura Zambonin; Luca Maria Neri; Alberto Maria Martelli; Francesca Chiarini
Journal:  J Hematol Oncol       Date:  2016-10-24       Impact factor: 17.388

5.  ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM.

Authors:  Xiang Zhang; Zhen Zhang; Qing Zhang; Quansheng Zhang; Peiqing Sun; Rong Xiang; Guosheng Ren; Shuang Yang
Journal:  Cell Death Dis       Date:  2018-01-19       Impact factor: 8.469

6.  Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 up-regulation.

Authors:  Yi Na Jiang; Hong Qiong Yan; Xiao Bo Huang; Yi Nan Wang; Qing Li; Feng Guang Gao
Journal:  Oncotarget       Date:  2015-12-01

Review 7.  Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer.

Authors:  Christine Koulis; Raymond Yap; Rebekah Engel; Thierry Jardé; Simon Wilkins; Gemma Solon; Jeremy D Shapiro; Helen Abud; Paul McMurrick
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

Review 8.  ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance.

Authors:  Stanislav Drápela; Jan Bouchal; Mohit Kumar Jolly; Zoran Culig; Karel Souček
Journal:  Front Mol Biosci       Date:  2020-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.